GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients

GoodRx Inc., America’s leading resource for healthcare savings, and Boehringer Ingelheim, a privately owned, leading global biopharmaceutical company, announced a collaborative effort to increase access to patient savings programs on the GoodRx platform. Patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD) can now easily enroll in manufacturer-sponsored copay programs for Boehringer Ingelheim’s leading portfolio of medications to help reduce their out-of-pocket costs, with additional medications that may be added to the integration in the future. This integration and proposed integrations have the potential to deliver approximately $15 million in available savings a year for those that need life-enhancing medications, based on internal estimates.

“As insurance deductibles increase, fewer medications are covered by insurance, and more restrictions are placed on the medications that are covered, patients are left carrying more of the economic burden,” said Bansi Nagji, President of Healthcare at GoodRx. “The integration of Boehringer Ingelheim savings programs will help lower the affordability barrier for patients so they can better access the medications they need.”

Consumers looking for manufacturer savings programs for diabetes or COPD can go directly to the GoodRx website to find options available from Boehringer Ingelheim. Those who qualify with commercial insurance can find savings programs for their prescription of Jardiance® (empagliflozin), Synjardy® (empagliflozin/metformin HCI), Synjardy XR® (empagliflozin/metformin HCI extended-release), Spiriva Respimat® (tiotropium bromide), Stiolto Respimat® (tiotropium bromide and olodaterol) and Combivent Respimat® (ipratropium bromide and albuterol).

“The combination of Boehringer Ingelheim’s commitment to the patients we serve and innovative approach to bringing transformative therapies to market, and GoodRx’s trusted brand and reach, means that we will be able to provide more patients with seamless access to our support and savings programs,” said Chris Marsh, Senior Vice President, Market Access, Boehringer Ingelheim Pharmaceuticals, Inc. “We look forward to expanding our collaborative partnership with GoodRx so we can help more people living with chronic conditions find the appropriate savings program that is right for them and lower their out-of-pocket costs.”